Use of Biologics for Severe Asthma in Hong Kong

Recruiting now

Conditions studied: Asthma

In brief

The landscape of biologics therapy used in Hong Kong is currently unknown. The purpose of this study is to conduct a retrospective analysis of the use of biologics treatment for severe asthma in Hong Kong. The study aims to assess the landscape of biologics usage, evaluate the characteristics and conditions of patients before and after receiving biologic therapy, and provide insights into the effectiveness and safety of these treatments in the local population.

Key facts

Study ID

NCT06778746

Run by

Chinese University of Hong Kong

People needed

360

Starts

2024-12-26

Expected to finish

2027-12-26

Last updated by the study team

2026-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 years or older.
• Patients diagnosed with severe asthma per the Global Initiative for Asthma (GINA) guidelines.
• Patients who have received biologic therapy for treatment of asthma (including those who received just one dose to allow assessment of the reason for withdrawal)

You may not qualify if…

• Patients with respiratory diseases with other known significant respiratory diseases, including tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer

Where it is running

• Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, HK — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.